Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...
13d
Reorganizing its generics business strategy to target 60% instead of 80% of drugs coming off patent and reallocating resources to complex generics will help Teva offset base business erosion and ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Biogen Inc. ( (BIIB)) has realeased its Q3 earnings. Here is a breakdown of the information Biogen Inc. presented to its investors. Biogen Inc. is a leading biotechnology company that specializes ...
Google Pixel Tablet 3 could be the laptop replacement we've been waiting for — here's what we know
Here’s how it works. This future third-generation tablet will drop in 2027 with the upgraded Tensor G6 chip that has previously been rumored to be built on a 3nm node. Apparently, Google will ...
The Nubia Red Magic Nova Tablet opens up an intriguing new market of gaming-focused tablets, and it’s a hugely capable runner at an impressively low price. Some work is still needed on the way ...
Biogen’s investors are growing restless. Wednesday’s third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year ...
Despite a somewhat ambling launch, Biogen’s Eisai-partnered Alzheimer’s disease drug Leqembi continues to grow. But to truly unlock the amyloid-busting antibody’s potential, the company will ...
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth Quarterly Leqembi sales reached $67 million, beating estimates Cost cuts to drive high-teen percentage operating income boost ...
(Bloomberg) -- Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance ...
Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go ...
Biogen raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven by ongoing cost-cutting measures and the strong performance of its new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback